Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Can Sagimet turn denifanstat into a multi-indication platform and licensing engine beyond acne? Can Sagimet parlay its acne win into a licensing engine and platform biotech story? Explore how FASN inhibition is being redefined across diseases. byPallavi MadhirajuOctober 27, 2025